A convergent trend is emerging in psychedelic neuroscience: psilocybin, its active metabolite psilocin, and related tryptamines like 5-MeO-DMT are being repositioned beyond psychiatric indications toward neurological and pain-related disorders, including chronic pain, neuropathic pain, and traumatic brain injury. The unifying mechanistic thread is 5-HT2A receptor agonism—demonstrated through pharmacological blockade experiments using antagonists such as M100907 and volinanserin—which drives downstream neuroplasticity, synaptogenesis, and functional connectivity changes in circuits governing self-referential processing, sensorimotor integration, and reward (nucleus accumbens, frontal cortex). Co-administration studies with NMDA receptor modulators (D-serine, D-cycloserine) show synergistic enhancement of plasticity markers (GAP43, PSD95) while dissociating therapeutic effects from hallucinogenic behavioral proxies like the head-twitch response, suggesting a path toward separating psychedelic potency from clinical efficacy.
A second major axis is neuroimmune modulation: psilocybin and psilocin suppress pro-inflammatory cytokines such as TNF-α in LPS-activated microglia and reduce microglial proliferation in hippocampal regions, implicating anti-inflammatory and neuroprotective mechanisms that parallel findings for 5-MeO-DMT in traumatic brain injury models (via TrkB and sigma-1 receptor pathways). This anti-inflammatory action, combined with preservation of reelin-positive neurogenic cells and upregulation of glucocorticoid and serotonin-2A receptor expression in stress models, positions psychedelics as multi-target agents capable of addressing neuroinflammation, HPA-axis dysregulation, and impaired neuroplasticity simultaneously—mechanisms directly relevant to chronic and neuropathic pain, which remain poorly controlled by conventional analgesics.
Translational and methodological themes reinforce this trajectory: pharmacokinetic characterization (HPLC-DAD quantification, gut microbiome interactions), dosing paradigm optimization, and safety profiling are being systematically addressed to support clinical translation, while animal models test antinociceptive, pro-cognitive (spatial memory, reversal learning), and antidepressant-like endpoints in parallel. Notably, some effects are dissociable and context-dependent—psilocybin fails to reverse apathy-related behavior and produces sex- and genotype-dependent locomotor/hyperactivity responses—highlighting that therapeutic benefit is circuit- and state-specific rather than a uniform psychedelic effect.
Collectively, these findings support an emerging trend: leveraging serotonergic psychedelics' shared capacity to engage 5-HT2A/TrkB-linked neuroplasticity and suppress neuroinflammation as a unifying therapeutic strategy across chronic pain, neuropathic pain, and traumatic brain injury—conditions historically treated as mechanistically distinct but now converging around common maladaptive plasticity and neuroinflammatory substrates that psychedelics may reverse.